Eur Rev Med Pharmacol Sci 2021; 25 (18): 5755-5765

DOI: 10.26355/eurrev_202109_26793

Biologics for psoriatic arthritis: network meta-analysis in review

A. Migliore, G. Gigliucci, D. Birra, R. Saporito, L. Cicerchia, U. Massafra, D. Integlia, M. Cassol

Rheumatology, S. Pietro Fatebenefratelli Hospital, Rome, Italy. migliore.alberto60@gmail.com


OBJECTIVE: A review of network meta-analysis to assess efficacy and safety of biologics for the treatment of psoriatic arthritis (PsA).

MATERIALS AND METHODS: A systematic search was conducted on electronic databases to identify Bayesian meta-analysis reporting clinical parameters of efficacy, safety and cost-effectiveness of biologics that are approved for the treatment of PsA patients.

RESULTS: We identified 19 studies and included them for review. There is insufficient statistical evidence to demonstrate clear differences in effectiveness between available biologic agents for PsA due to many differences in methods and clinical parameters reported in the studies. Old biologics are reported to be safe.

CONCLUSIONS: New molecules approved for the treatment of PsA appear promising treatments but further comparative studies methodologically well-conducted are necessary. It is also necessary to follow strictly international recommendations to conduct NMA to better help physicians and decision-makers in making appropriate decisions.

 

Free PDF Download

To cite this article

A. Migliore, G. Gigliucci, D. Birra, R. Saporito, L. Cicerchia, U. Massafra, D. Integlia, M. Cassol
Biologics for psoriatic arthritis: network meta-analysis in review

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 18
Pages: 5755-5765
DOI: 10.26355/eurrev_202109_26793